SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-21-005789
Filing Date
2021-05-05
Accepted
2021-05-05 07:00:44
Documents
13
Period of Report
2021-05-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20210504x8k.htm   iXBRL 8-K 37209
2 EX-10.1 kala-20210504xex10d1.htm EX-10.1 358807
  Complete submission text file 0001558370-21-005789.txt   603222

Data Files

Seq Description Document Type Size
3 EX-101.SCH kala-20210504.xsd EX-101.SCH 3028
4 EX-101.LAB kala-20210504_lab.xml EX-101.LAB 16735
5 EX-101.PRE kala-20210504_pre.xml EX-101.PRE 10607
6 EXTRACTED XBRL INSTANCE DOCUMENT kala-20210504x8k_htm.xml XML 5011
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 21891113
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences